Merck (MRK) Tops Q3 EPS by 7c; narrows guidance range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
November 1, 2024 7:20 AM EDTLeerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).
The analyst comments "Bottom Line: Gardasil remained the primary topic for Merck (MRK, OP) earnings and continues to weigh on the stock, which is trading at a 13.6 PE multiple, below most of its... More
